<DOC>
	<DOCNO>NCT00407459</DOCNO>
	<brief_summary>The primary objective ass antitumor activity combination bevacizumab , pemetrexed carboplatin , term time progression .</brief_summary>
	<brief_title>Phase II Study Bevacizumab , Pemetrexed Carboplatin First-Line Therapy Malignant Pleural Mesothelioma</brief_title>
	<detailed_description>Secondary endpoint evaluate : - objective response rate ( RR ) combination ; - toxicity safety profile combination ; - duration response ( RD ) time treatment failure ( TTF ) ; - overall survival ( OS ) - RR , TTP OS accord baseline plasma VEGF level ( introduce Amendment 1 date 8/11/2007 )</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically proven malignant pleural mesothelioma , inoperable , non previously treat chemotherapy include intracavitary administration PS 01 Measurable and/or evaluable lesion accord RECIST criterion Adequate organ function Uncontrolled hypertension Evidence bleed diathesis coagulopathy Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>